WHO's First-Ever Global Guideline on Obesity Treatment: Conditional Nod to GLP-1 Drugs Including Semaglutide

Geneva, June 12, 2026. Recognising obesity as a serious global health challenge, the World Health Organization (WHO) has issued its first-ever global guideline on the use of GLP-1 drugs to treat the condition. The guideline is being seen as a landmark step, as it conditionally recommends these medicines for the treatment of obesity in adults at a global level for the first time. The recommendation goes a step further than the listing of these drugs on the Essential Medicines List in September 2025.

Which Drugs Are Included

The WHO guideline specifically names three GLP-1 medicines: liraglutide, semaglutide and tirzepatide. According to the guideline, adults, excluding pregnant women, may use these medicines as part of long-term obesity treatment. WHO defines obesity as a body mass index (BMI) of 30 or higher. The organisation has made clear that the recommendation is 'conditional', reflecting limited data on long-term efficacy and safety, current costs and equity concerns surrounding access to these therapies.

The Growing Obesity Crisis

Figures show that obesity now affects more than one billion people worldwide. In 2024, obesity was associated with 3.7 million deaths, and it is estimated that its prevalence could double by 2030. These numbers demonstrate that obesity is no longer merely a lifestyle issue but has become a serious, chronic and relapsing disease that requires comprehensive medical intervention. India is not untouched by this crisis either, with obesity rising rapidly in urban areas alongside diabetes.

The WHO Chief's Caution

WHO Director-General Dr Tedros Adhanom Ghebreyesus made an important point on the occasion. He said that medication alone will not solve this global health crisis, but that these therapies can help millions of people overcome obesity. The organisation stressed that the use of these drugs should be part of a comprehensive approach that includes healthy diets, regular physical activity and support from health professionals. This message dispels the misconception that these drugs work like a magic solution on their own.

Concerns and Challenges

The guideline also highlights several important concerns. These include gaps in long-term safety data, uncertainty about weight regain after discontinuing the drugs, the high cost of these medicines, the inadequate preparedness of health systems, and the circulation of falsified and substandard products in the market. These challenges underline that the drugs must be used only with caution and under medical supervision. Using them without a doctor's advice can be dangerous and counterproductive.

The Question of Equity and Access

WHO has raised a serious concern that, under current conditions, these drugs will reach fewer than 10 percent of eligible patients by 2030. To address this inequity, the organisation has advocated strategies such as pooled procurement, tiered pricing and voluntary licensing. This is particularly important for developing countries like India, where obesity and diabetes are rising rapidly, but access to expensive medicines remains a major barrier. The production of affordable generic versions could play a decisive role here.

The Social and Economic Burden of Obesity

Obesity is not just a medical problem; its social and economic burden is also enormous. It increases the risk of diabetes, heart disease, high blood pressure and several types of cancer, placing heavy pressure on health systems. It also affects the economy through reduced productivity and rising treatment costs. The WHO guideline acknowledges that tackling obesity requires not only individual effort but also systemic and policy-level interventions, including changes to food environments and urban planning.

What It Means for India

For India, the WHO guideline arrives at a critical moment. The country is witnessing a rapid rise in obesity, particularly in cities, alongside one of the world's largest diabetes burdens. Demand for GLP-1 drugs has surged globally, pushing up prices and creating shortages that hit poorer countries hardest. Indian pharmaceutical companies, known for producing affordable generic medicines at scale, could play a decisive role once patents allow, potentially making these therapies accessible to far more patients. Public health experts caution, however, that drugs must complement, not replace, investment in healthier diets, physical activity and preventive care.

What's Next

WHO has announced that it will develop an evidence-based prioritisation framework to determine which adults with obesity should be prioritised for GLP-1 treatment as supply and system capacity expand. The guideline marks an important turning point in the global fight against obesity, but its real success will depend on how equitably and safely these drugs are delivered to those who need them most. In the coming months, several countries may incorporate these recommendations into their national policies.